Sugi Predict

Sugi Predict / Compounds / SCHEMBL725082

SCHEMBL725082

SCHEMBL725082

COc1cc(C(=O)n2ccnc2-c2ccccc2)cc(OC)c1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ F2 P00734 1/20 0.51
▸ PLAU P00749 1/20 0.51
▸ KLKB1 P03952 1/20 0.51
▸ ELANE P08246 1/20 0.51
▸ SIRT5 Q9NXA8 1/20 0.51
▸ TUBB1 Q9H4B7 9/20 0.50
▸ TUBB4A P04350 8/20 0.50
▸ TUBB P07437 8/20 0.50
▸ TUBA3C P0DPH7 8/20 0.50
▸ TUBA1B P68363 8/20 0.50
▸ TUBA4A P68366 8/20 0.50
▸ TUBB4B P68371 8/20 0.50
▸ TUBB3 Q13509 8/20 0.50
▸ TUBB2A Q13885 8/20 0.50
▸ TUBB8 Q3ZCM7 8/20 0.50
▸ TUBA3E Q6PEY2 8/20 0.50
▸ TUBA1A Q71U36 8/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25176183 0.85 ELANE (0.46) CYP1A2F2PLAUKLKB1ELANE
SCHEMBL725309 0.81 KMT2A (0.53) ALDH1A1CYP1A2F2KMT2AMAPT
SCHEMBL786798 0.79 ESR1 (0.50) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL31188467 0.79 TUBB4A (0.55) F2PLAUKLKB1ELANESIRT5
SCHEMBL616402 0.72 ESR1 (0.43) MAPT
SCHEMBL11078694 0.71 ESR1 (0.54) ALDH1A1CYP1A2KMT2AKDM4EMAPT
SCHEMBL28848047 0.71 ESR1 (0.54) ALDH1A1CYP1A2KMT2AKDM4EMAPT
SCHEMBL786660 0.71 TUBB4A (0.69) ALDH1A1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL2450750 0.70 TUBB4A (0.72) ALDH1A1CYP1A2TUBB1TUBB4ATUBB
SCHEMBL10782342 0.70 ESR1 (0.50) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 — — US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 — — US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 — — WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 THRB 2822/4885ALDH1A1 209/4885CYP1A2 4356/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 THRB 2822/4885ALDH1A1 209/4885CYP1A2 4356/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 THRB 3743/4885ALDH1A1 3707/4885CYP1A2 4686/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 THRB 2822/4885ALDH1A1 209/4885CYP1A2 4356/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB THRB 3399/4885ALDH1A1 2765/4885CYP1A2 4309/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 THRB 2822/4885ALDH1A1 209/4885CYP1A2 4356/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 THRB 2822/4885ALDH1A1 209/4885CYP1A2 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.